Kaempferol as a therapeutic agent in Alzheimer's disease : Evidence from preclinical studies
Copyright © 2023 Elsevier B.V. All rights reserved..
BACKGROUND: Alzheimer's disease (AD) is the most common type of dementia and seriously affects human life and health. Kaempferol (KMP) is a common flavonoid, that is mainly derived from the rhizomes of Kaempferol galanga L. and is widely found in various fruits and vegetables. Previous studies have suggested that KMP has multiple pharmacological activities. However, the anti-AD mechanism of KMP has not been elucidated.
METHODS: This systematic review aims to summarize the existing preclinical experiments on KMP, further confirm the therapeutic effect of KMP in an AD model, and summarize the possible mechanism by which KMP exerts anti-AD effects. Electronic databases, including PubMed, China National Knowledge Infrastructure (CNKI), Baidu Academic, and Wanfang, were searched using the keywords of 'Kaempferol,' 'KMP,' 'pharmacology,' and 'Alzheimer's disease'.
RESULTS: We evaluated the reliability of the 12 included studies, and the results showed that the anti-AD mechanism of KMP was reliable and that the prospect of KMP in the treatment of cognitive impairment was promising. We comprehensively assessed the neuroprotective effects of KMP in in vivo and in vitro models of AD. These studies shown that KMP ameliorated AD through several mechanisms, including its antioxidant, anti-inflammatory, anti-apoptotic, and anti-acetylcholinesterase effects.
CONCLUSION: KMP may exert anti-AD effects through various mechanisms and is a potential drug with broad prospects for the treatment of AD.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:87 |
---|---|
Enthalten in: |
Ageing research reviews - 87(2023) vom: 15. Juni, Seite 101910 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Dong, Xiaoyu [VerfasserIn] |
---|
Links: |
---|
Themen: |
Aβ |
---|
Anmerkungen: |
Date Completed 09.05.2023 Date Revised 09.05.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.arr.2023.101910 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM354300849 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM354300849 | ||
003 | DE-627 | ||
005 | 20231226061920.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.arr.2023.101910 |2 doi | |
028 | 5 | 2 | |a pubmed24n1180.xml |
035 | |a (DE-627)NLM354300849 | ||
035 | |a (NLM)36924572 | ||
035 | |a (PII)S1568-1637(23)00069-7 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Dong, Xiaoyu |e verfasserin |4 aut | |
245 | 1 | 0 | |a Kaempferol as a therapeutic agent in Alzheimer's disease |b Evidence from preclinical studies |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 09.05.2023 | ||
500 | |a Date Revised 09.05.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2023 Elsevier B.V. All rights reserved. | ||
520 | |a BACKGROUND: Alzheimer's disease (AD) is the most common type of dementia and seriously affects human life and health. Kaempferol (KMP) is a common flavonoid, that is mainly derived from the rhizomes of Kaempferol galanga L. and is widely found in various fruits and vegetables. Previous studies have suggested that KMP has multiple pharmacological activities. However, the anti-AD mechanism of KMP has not been elucidated | ||
520 | |a METHODS: This systematic review aims to summarize the existing preclinical experiments on KMP, further confirm the therapeutic effect of KMP in an AD model, and summarize the possible mechanism by which KMP exerts anti-AD effects. Electronic databases, including PubMed, China National Knowledge Infrastructure (CNKI), Baidu Academic, and Wanfang, were searched using the keywords of 'Kaempferol,' 'KMP,' 'pharmacology,' and 'Alzheimer's disease' | ||
520 | |a RESULTS: We evaluated the reliability of the 12 included studies, and the results showed that the anti-AD mechanism of KMP was reliable and that the prospect of KMP in the treatment of cognitive impairment was promising. We comprehensively assessed the neuroprotective effects of KMP in in vivo and in vitro models of AD. These studies shown that KMP ameliorated AD through several mechanisms, including its antioxidant, anti-inflammatory, anti-apoptotic, and anti-acetylcholinesterase effects | ||
520 | |a CONCLUSION: KMP may exert anti-AD effects through various mechanisms and is a potential drug with broad prospects for the treatment of AD | ||
650 | 4 | |a Systematic Review | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Alzheimer’s disease | |
650 | 4 | |a Aβ | |
650 | 4 | |a Kaempferol | |
650 | 4 | |a Natural sources | |
650 | 4 | |a Neuroprotection | |
650 | 4 | |a Systematic review | |
650 | 7 | |a Kaempferols |2 NLM | |
650 | 7 | |a Antioxidants |2 NLM | |
700 | 1 | |a Zhou, Siyu |e verfasserin |4 aut | |
700 | 1 | |a Nao, Jianfei |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Ageing research reviews |d 2002 |g 87(2023) vom: 15. Juni, Seite 101910 |w (DE-627)NLM119138735 |x 1872-9649 |7 nnns |
773 | 1 | 8 | |g volume:87 |g year:2023 |g day:15 |g month:06 |g pages:101910 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.arr.2023.101910 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 87 |j 2023 |b 15 |c 06 |h 101910 |